Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies

Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies

IntroductionZabedosertib, the interleukin-1 receptor-associated kinase-4 (IRAK4) inhibitor, is in clinical development as an oral therapeutic for immune-mediated inflammatory diseases and was thoroughly investigated in several phase 1 studies in healthy male volunteers.MethodsPharmacokinetics, safet...

Full description

Saved in:
Bibliographic Details
Main Authors: Maximilian Feldmüller, Stefan J. Jodl, Bart Ploeger, Andrea Wagenfeld, Herbert Wiesinger, Frank S. Zollmann, Stefan Klein, Ruiping Zhang, Beate Rohde, Joachim Höchel
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pharmacology
Subjects:
safety
pharmacokinetics
pharmacodynamics IRAK4
IRAK4 inhibitor
immune-mediated inflammatory disorders
pharmacodynamics
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1521505/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1521505/full

Similar Items